Novartis Gains Access to Celyad’s allogenic CAR-T cell patents – Labiotech.eu (blog)
|
Novartis Gains Access to Celyad's allogenic CAR–T cell patents
Labiotech.eu (blog) Belgian Celyad is giving Novartis access to its IP for the production of allogeneic CAR–T cells in a non-exclusive license agreement, worth up to €88M. Celyad is developing “off-the-shelf” therapies, based on engineering donor-derived allogeneic T cells. Celyad (CYAD), Novartis (NVS) Enter Non-Exclusive License for Allogeneic TCR-Deficient CAR–T Cells Novartis takes the long view on CAR–T, grabbing licenses on new tech for next-gen therapies |
